Trial Profile
Population-based pharmacokinetic and pharmacodynamic dosing model of epirubicin, cyclophosphamide and docetaxel for breast cancer [Populationsbaseret farmakokinetisk og farmakodynamisk doseringsmodel af epirubicin, cyklofosfamid og docetaxel til brystkraeft]
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2013
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 26 Jan 2013 Status changed from recruiting to discontinued.
- 15 Jun 2011 New trial record